Publication Date
10-3-2023
Journal
The Journal of Infectious Diseases
DOI
10.1093/infdis/jiad334
PMID
37669225
PMCID
PMC10547463
PubMedCentral® Posted Date
9-5-2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Antiviral Agents, Drug Discovery, Biological Assay, 3D tissue models, SARS-CoV-2, antiviral drug discovery, body-on-a-chip, human pluripotent stem cells (hPSCs), induced pluripotent stem cells (iPSCs), microphysiological systems (MPS), organ-on-a-chip, organoid, tissue-derived stem cells
Abstract
The National Center for Advancing Translational Sciences (NCATS) Assay Guidance Manual (AGM) Workshop on 3D Tissue Models for Antiviral Drug Development, held virtually on 7-8 June 2022, provided comprehensive coverage of critical concepts intended to help scientists establish robust, reproducible, and scalable 3D tissue models to study viruses with pandemic potential. This workshop was organized by NCATS, the National Institute of Allergy and Infectious Diseases, and the Bill and Melinda Gates Foundation. During the workshop, scientific experts from academia, industry, and government provided an overview of 3D tissue models' utility and limitations, use of existing 3D tissue models for antiviral drug development, practical advice, best practices, and case studies about the application of available 3D tissue models to infectious disease modeling. This report includes a summary of each workshop session as well as a discussion of perspectives and challenges related to the use of 3D tissues in antiviral drug discovery.